Innovation
Innovation
Improving Health for All
We develop new ways to promote faster development of valuable treatments and ensure diverse patient groups can access them.
Featured White Paper
The Elasticity of Pharmaceutical Innovation: How Much Does Revenue Drive New Drug Development?
For every 10% reduction in expected revenues, we can expect 2.5% to 15% less pharmaceutical innovation. Policymakers should take care to balance reductions in health outcomes long-term with short-term access improvements.
Experts: Karen Van Nuys, Darius Lakdawalla, Dana Goldman
Top Innovation Stories View All
Comment Letter
Comments on the Commissioner’s National Priority Voucher Pilot Program
Featured Experts: Lowell Schiller
In The News View All
STAT News
Schiller urges FDA to establish formal procedures for commissioner’s voucher program
Featured Experts: Lowell Schiller
WGBH
Kanter addresses psychedelics executive order and outlines concerns with the FDA commissioner’s voucher program
Featured Experts: Genevieve P. Kanter
Bloomberg
Lakdawalla explains why MFN could hold back new treatments in Europe
Featured Experts: Darius Lakdawalla
Financial Times
Medicare’s plan to speed up coverage of new medical devices may expand access to innovation, Padula says
Featured Experts: William Padula
Axios
Schiller says China’s rise in drug development could upend U.S. R&D models
Featured Experts: Lowell Schiller
Related Subtopics
High drug prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. We connect industry, academia and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Team View All Innovation Experts
